34 related articles for article (PubMed ID: 35946566)
1. Severe adverse cutaneous reactions induced by gefitinib combined with antihypertensive and antihyperlipidemic drugs in lung cancer: a case report.
Shen X; Fan G; Liu G; Wang F; Li Q; Liu X; Zhu H; Zhu Y; Lu J; Wang S
Anticancer Drugs; 2022 Jan; 33(1):e802-e807. PubMed ID: 34459464
[TBL] [Abstract][Full Text] [Related]
2. The Effects of Drug Exposure and Single Nucleotide Polymorphisms on Aaptinib-Induced Severe Toxicities in Solid Tumors.
Chen Y; Lin Y; Guan S; Zhao Z; Lin D; Guan J; Zhou C; Liu J; Cao X; Lin Z; Chen D; Shang J; Zhang W; Chen H; Chen L; Ma S; Gu L; Zhao J; Huang M; Wang X; Long H
Drug Metab Dispos; 2023 Dec; 51(12):1583-1590. PubMed ID: 37775332
[TBL] [Abstract][Full Text] [Related]
3. Cyp3A4 *1G polymorphism is associated with alcohol drinking: A 5-year retrospective single centered population-based study in China.
Jia X; Zhang X; Zhou T; Sun D; Li R; Yang N; Luo Z
PLoS One; 2023; 18(12):e0295184. PubMed ID: 38117809
[TBL] [Abstract][Full Text] [Related]
4. Kinase Inhibitors FDA Approved 2018-2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities.
Latham BD; Geffert RM; Jackson KD
Drug Metab Dispos; 2024 May; 52(6):479-492. PubMed ID: 38286637
[TBL] [Abstract][Full Text] [Related]
5. Machine learning in onco-pharmacogenomics: a path to precision medicine with many challenges.
Mondello A; Dal Bo M; Toffoli G; Polano M
Front Pharmacol; 2023; 14():1260276. PubMed ID: 38264526
[TBL] [Abstract][Full Text] [Related]
6. Editorial: RNA and RNA modification in the pathogenesis, diagnosis and treatment of cancers, Volume II.
Lu Q; Wang L; Zhang JY; Yang DH
Front Oncol; 2023; 13():1164399. PubMed ID: 36968996
[No Abstract] [Full Text] [Related]
7. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
8. Gefitinib for advanced non-small cell lung cancer.
Sim EH; Yang IA; Wood-Baker R; Bowman RV; Fong KM
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD006847. PubMed ID: 29336009
[TBL] [Abstract][Full Text] [Related]
9. Association of genetic polymorphisms of CYP3A4 and CYP2D6 with gefitinib-induced toxicities.
Kwok WC; Lam DCL; Ip MSM; Tam TCC; Ho JCM
Anticancer Drugs; 2022 Nov; 33(10):1139-1144. PubMed ID: 35946566
[TBL] [Abstract][Full Text] [Related]
10. Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer.
Suzumura T; Kimura T; Kudoh S; Umekawa K; Nagata M; Matsuura K; Tanaka H; Mitsuoka S; Yoshimura N; Kira Y; Nakai T; Hirata K
BMC Cancer; 2012 Dec; 12():568. PubMed ID: 23207012
[TBL] [Abstract][Full Text] [Related]
11. Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes.
Han SY; Zhao HY; Zhou N; Zhou F; Li PP
J Ethnopharmacol; 2014; 151(1):210-7. PubMed ID: 24157377
[TBL] [Abstract][Full Text] [Related]
12. Effect of genetic polymorphisms on the pharmacokinetics of gefitinib in healthy Chinese volunteers.
Chen YR; Yu X; Xu LM; Mei J; Tian ML; Xu M; Jin QY; Ye LB; Yang SX
Xenobiotica; 2024 Jan; 54(1):38-44. PubMed ID: 38085693
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity.
Takimoto T; Kijima T; Otani Y; Nonen S; Namba Y; Mori M; Yokota S; Minami S; Komuta K; Uchida J; Imamura F; Furukawa M; Tsuruta N; Fujio Y; Azuma J; Tachibana I; Kumanogoh A
Clin Lung Cancer; 2013 Sep; 14(5):502-7. PubMed ID: 23664723
[TBL] [Abstract][Full Text] [Related]
14. Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations.
Sugiyama E; Umemura S; Nomura S; Kirita K; Matsumoto S; Yoh K; Niho S; Ohmatsu H; Tsuboi M; Ohe Y; Goto K
Lung Cancer; 2015 Nov; 90(2):307-13. PubMed ID: 26323212
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
